NCT04207463 2020-06-17A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsChia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 Unknown150 enrolled